| Xalatan (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop qpm (optimal), (AM dosing is considered acceptable.) |
| Chem Specs | latanoprost 0.005% |
| Quantities | 2.5ml |
| Cost | 44.46 generic |
| Class | prostaglandin analog (as an isopropyl ester prodrug) |
| Action | Increased uveoscleral aqueous outflow (possibly by loosening intercellular spaces.) 28% - 30% IOP reduction |
| Usage | Indicated for reduction of IOP in open angle glaucoma or ocular hypertension. IOP reduction starts in 3-4 hours. Maximum effect in 8–12 hours. |
| Side Effects | Generally less hyperemia, less pigmentation of iris, lids, and lashes than Lumigan. Possible cystoid macular edema in pseudophakes and/or aphakes. May exacerbated iritis/uveitis. Possible reactivation of herpes simplex and zoster. Dry eye-like surface inflammation observed in mice.1 Avoid with inflammatory glaucomas and surface eye disease. |
| Contraindications | Hypersensitivity to Xalantan or any other ingredient in the product. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. Has been used in children as young as 5 yrs without notable problems.2 |
| Pregnancy | Category C Embryofetal lethality shown in rats and rabbits at clinically relevant doses. |
| 0.05% BAK preserved. | |
| IOP lowering effects, drop size, and ingredient dosage in the generic has been questioned. Narayanaswamy A, Neog A, Baskaran M, et al., Indian J Ophthalmol 2007;55:127–31 |
2. Younus M, et al. Am J Ophthalmol. 2018;doi:10.1016/j.ajo.2018.08.039. N.L.M. DailyMed page for Trusopt PDR page for Trusopt